Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Zoom Video Communications, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while Zoom Video Communications, Inc. trades at $92.63 (market cap $26.73B). The key difference: Zoom Video Communications, Inc. is far larger — about 3.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | ZM | |
|---|---|---|
Market Cap | $8.04B | $26.73B |
Sector | Health | Technology |
52-Week High | $339.75 | $111.88 |
52-Week Low | $241.71 | $69.77 |
Enterprise Value | $7.85B | $19.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Zoom Communications (ZM) trades at $91.88, up 2.36% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong profitability with a net income margin of 41.99% and a P/E ratio of 13.53, trading below the analyst consensus price target of $118.79. Recent developments include the acquisition of Common Room and expansion of AI-powered Zoom Virtual Agent capabilities, signaling growth initiatives.
The outlook for ZM is positive, supported by robust cash flow, AI integration, and an undervalued stake in Anthropic ahead of its IPO. Risks include competitive pressure from Microsoft and Google, insider selling, and fluctuating cash flow trends. Wall Street sentiment is mixed, with 39% of analysts rating it a buy, but the stock offers value if execution on AI-driven growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
